28.10.2015 • NewsDede WillamsM%26ADow Chemical

Dow to Build Shale-fed MEG Plant in US

Dow Chemical is shifting at least some of its investment priorities to the US from the Middle East, and in particular restructuring its engagement in Kuwait.

The forward-looking plans for a corporate makeover announced by CEO Andrew Liveris last week include, alongside the possible divestment of the farm chemicals business, the sale of Dow’s stake in its Kuwaiti joint ventures MEGlobal and Equate. Proceeds would be reinvested in the US Gulf petrochemical business.

After exiting the direct joint venture at the end of the year, Dow would receive cash of $1.5 billion but would maintain a minority interest in MEG Global through another jv with Kuwaiti partner Petrochemical Industries Company at least until 2016.

Without disclosing details, Liveris said MEGlobal will build an MEG plant somewhere on the US Gulf to take advantage of cheap shale gas-derived feedstock. The decision of where to invest would depend on incentives offered, the Dow CEO said.

The governor of the Gulf Coast state of Louisiana has stood out recently, offering enticing investment subsidies for international companies building new facilities there.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
29.10.2024 • News

GSK to Invest $800 Million in US Manufacturing Facility

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.